Heterocyclic analgesic compounds and methods of use thereof
First Claim
Patent Images
1. A compound represented by A:
-
whereinm is 1, 2, 3 or 4;
n is 1 or 2;
y is 1 or 2;
R1 represents aryl, monocyclic or bicyclic heteroaryl with 5-12 ring atoms, of which one to three ring atoms are selected independently from the group consisting of S, O, and N;
or cycloalkyl;
R2 represents independently for each occurrence H, alkyl, fluoroalkyl, or cycloalkyl;
R3 represents independently for each occurrence H, C1-C10 alkyl, aryl, OR2, OC(O)R2, CH2OR2, or CO2R2;
wherein any two instances of R3 may be connected by a covalent tether whose backbone consists of 1, 2, 3, or 4 carbon atoms;
R4 represents independently for each occurrence aryl, monocyclic or bicyclic heteroaryl with 5-12 ring atoms, of which one to three ring atoms are selected independently from the group consisting of S, O, and N;
alkenyl, or cycloalkyl;
R5 represents independently for each occurrence H, C1-C10 alkyl, CH2Y, aryl, monocyclic or bicyclic heteroaryl with 5-12 ring atoms, of which one to three ring atoms are selected independently from the group consisting of S, O, and N;
F, OR2, or OC(O)R2;
R6 represents independently for each occurrence H, C1-C10 alkyl, CH2Y, aryl, monocyclic or bicyclic heteroaryl with 5-12 ring atoms, of which one to three ring atoms are selected independently from the group consisting of S, O, and N;
F, OR2, or OC(O)R2;
Y represents independently for each occurrence OR2, N(R2)2, SR2, S(O)R2, S(O)2R2, or P(O)(OR2)2;
X represents C(R3)2, or C═
O; and
the stereochemical configuration at any stereocenter of a compound represented by A is R, S, or a mixture of these configurations.
2 Assignments
0 Petitions
Accused Products
Abstract
One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-coupled receptors, and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds as analgesics.
-
Citations
32 Claims
-
1. A compound represented by A:
-
wherein m is 1, 2, 3 or 4;
n is 1 or 2;
y is 1 or 2;
R1 represents aryl, monocyclic or bicyclic heteroaryl with 5-12 ring atoms, of which one to three ring atoms are selected independently from the group consisting of S, O, and N;
or cycloalkyl;
R2 represents independently for each occurrence H, alkyl, fluoroalkyl, or cycloalkyl;
R3 represents independently for each occurrence H, C1-C10 alkyl, aryl, OR2, OC(O)R2, CH2OR2, or CO2R2;
wherein any two instances of R3 may be connected by a covalent tether whose backbone consists of 1, 2, 3, or 4 carbon atoms;
R4 represents independently for each occurrence aryl, monocyclic or bicyclic heteroaryl with 5-12 ring atoms, of which one to three ring atoms are selected independently from the group consisting of S, O, and N;
alkenyl, or cycloalkyl;
R5 represents independently for each occurrence H, C1-C10 alkyl, CH2Y, aryl, monocyclic or bicyclic heteroaryl with 5-12 ring atoms, of which one to three ring atoms are selected independently from the group consisting of S, O, and N;
F, OR2, or OC(O)R2;
R6 represents independently for each occurrence H, C1-C10 alkyl, CH2Y, aryl, monocyclic or bicyclic heteroaryl with 5-12 ring atoms, of which one to three ring atoms are selected independently from the group consisting of S, O, and N;
F, OR2, or OC(O)R2;
Y represents independently for each occurrence OR2, N(R2)2, SR2, S(O)R2, S(O)2R2, or P(O)(OR2)2;
X represents C(R3)2, or C═
O; and
the stereochemical configuration at any stereocenter of a compound represented by A is R, S, or a mixture of these configurations. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)
administering to a mammal with pain, drug addiction, or tinnitus an effective amount of a formulation of claim 24.
-
-
26. The method of claim 25, wherein said mammal is a primate, equine, canine or feline.
-
27. The method claim 25, wherein said mammal is a human.
-
28. The method of claim 25, wherein said formulation is administered orally.
-
29. The method of claim 25, wherein said formulation is administered intravenously.
-
30. The method of claim 25, wherein said formulation is administered sublingually.
-
31. The method of claim 25, wherein said formulation is administered ocularly.
-
32. A compound represented by A:
-
wherein m is 1, 2, 3 or 4;
n is 1 or 2;
y is 1 or 2;
R1 represents monocyclic or bicyclic heteroaryl with 5-12 ring atoms, of which one to three ring atoms are selected independently from the group consisting of S, O, and N;
or cycloalkyl;
R2 represents heteroaryl;
R3 represents independently for each occurrence H, C1-C10 alkyl, aryl, OR2, OC(O)R2, CH2OR2, or CO2R2;
wherein any two instances of R3 may be connected by a covalent tether whose backbone consists of 1, 2, 3, or 4 carbon atoms;
R4 represents independently for each occurrence H, alkyl, aryl, monocyclic or bicyclic heteroaryl with 5-12 ring atoms, of which one to three ring atoms are selected independently from the group consisting of S, O, and N;
alkenyl, or cycloalkyl;
R5 represents independently for each occurrence H, C1-C10 alkyl, CH2Y, aryl, monocyclic or bicyclic heteroaryl with 5-12 ring atoms, of which one to three ring atoms are selected independently from the group consisting of S, O, and N;
F, OR2, or OC(O)R2;
R6 represents independently for each occurrence H, C1-C10 alkyl, CH2Y, aryl, monocyclic or bicyclic heteroaryl with 5-12 ring atoms, of which one to three ring atoms are selected independently from the group consisting of S, O, and N;
F, OR2, or OC(O)R2;
Y represents independently for each occurrence OR2, N(R2)2, SR2, S(O)R2, S(O)2R2, or P(O)(OR2)2;
X represents C(R3)2, or C═
O; and
the stereochemical configuration at any stereocenter of a compound represented by A is R, S, or a mixture of these configurations.
-
Specification